<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250184</url>
  </required_header>
  <id_info>
    <org_study_id>GrupoRS0001</org_study_id>
    <nct_id>NCT01250184</nct_id>
  </id_info>
  <brief_title>Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy.</brief_title>
  <official_title>Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Rehabilitacion en Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Rehabilitacion en Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Myofascial pain syndrome (MPS) of the shoulder girdle and cervical region is a
      common musculoskeletal problem that is often chronic or recurrent. It has demonstrated the
      effectiveness of different treatments such as exercise, injection but not comparing them with
      each other. The objective of this research was to demonstrate whether lidocaine injection
      into trigger points combined with a physical therapy program was more effective than each
      separatetreatment in improving pain, function and quality of life in a group of patients with
      myofascial pain syndrome (MPS) of the shoulder girdle and cervical region.

      Design: Single-blind, randomized, controlled clinical trial with three parallel groups in the
      departments of physical medicine and rehabilitation of two urban hospitals. There were 127
      patients with myofascial pain in the shoulder girdle for more than six weeks in length and
      pain greater than 40 mm on the visual analog scale (VAS). There were three intervention
      groups: physical therapy (PT), lidocaine injection (LI), or the combination of both (PT +
      LI). The primary outcome at one month was the VAS, and the secondary outcomes were measured
      using the SF36 pain scaleat one and three months.

      Keywords: Myofascial pain, trigger points, lidocaine injection, physical therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose a double blind randomized controlled clinical trial, in different health centers
      in Medellin. The subjects are patients with myofascial trigger points (MTP) in muscles of the
      shoulder girdle (levator scapulae, trapezius, infraspinatus) diagnosed by neck ans shoulder
      pain lasting langer than 6 weeks, and that have not received rehabilitation treatment and are
      not currently taking analgesic medications. We have calculated a sample of 45 patients in
      each group.

      The physical and rehabilitation doctors who evaluated the patients and the nurse who assessed
      the patients were blinded to treatment allocation. Physicians who performed the MTP injection
      did not participate in the evaluation of primary and secondary outcomes. Physical therapists
      who conducted the therapeutic exercise program did not participate in the evaluation of
      primary and secondary outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>4 weeks</time_frame>
    <description>VAS with a score of 0-100, where 100 is the value representing the highest degree of pain and 0 the lowest. Successful treatment was defined as a reduction in pain of at least 20% of the previous score on the VAS after 4 weeks of the initial evaluation, or 14 mm on the VAS; this scale is a reliable pain assessment measure that has been validated previously</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>VAS with a score of 0-100, where 100 is the value representing the highest degree of pain and 0 the lowest. Successful treatment was defined as a reduction in pain of at least 20% of the previous score on the VAS after 4 weeks of the initial evaluation, or 14 mm on the VAS; this scale is a reliable pain assessment measure that has been validated previously</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PHQ 9 Function Measured With the Hand Back and Hand Mouth Maneuvers. Complications and Adverse Reactions Need for Rescue Medication</measure>
    <time_frame>4 weeks</time_frame>
    <description>The PHQ-9 was developed from the Primary Care Evaluation of Mental Disorders. The self-report instrument asks individuals how much they had been bothered by any of the nine problems over the prior two weeks. Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents the severity of depressive symptoms. 0 - 4 None-minimal None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe, 20 - 27 Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life SF-36</measure>
    <time_frame>4 weeks</time_frame>
    <description>The SF-36 consists of 36 items addressing the patient's perception of their quality of life (QoL) in the following eight domains: physical function (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH), and one item change in health. Sub-scale scores range from 0 to 100, with 100 as the best, most positive QoL in that area and 0 is the worst. There is a total scale score, all subscales range from 0 to 100. This scale was validated in Colombia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHQ 9 Function Measured With the Hand Back and Hand Mouth Maneuvers. Complications and Adverse Reactions Need for Rescue Medication</measure>
    <time_frame>12 weeks</time_frame>
    <description>The PHQ-9 was developed from the Primary Care Evaluation of Mental Disorders. The self-report instrument asks individuals how much they had been bothered by any of the nine problems over the prior two weeks. Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents the severity of depressive symptoms. 0 - 4 None-minimal None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe, 20 - 27 Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life SF-36</measure>
    <time_frame>12 weeks</time_frame>
    <description>The SF-36 consists of 36 items addressing the patient's perception of their quality of life (QoL) in the following eight domains: physical function (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH), and one item change in health. Sub-scale scores range from 0 to 100, with 100 as the best, most positive QoL in that area and 0 is the worst. There is a total scale score, all subscales range from 0 to 100. This scale was validated in Colombia.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Myofascial Pain Syndrome</condition>
  <condition>Pain</condition>
  <condition>Myofascial Trigger Point Pain</condition>
  <condition>Musculoskeletal Pain</condition>
  <arm_group>
    <arm_group_label>Physical Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twelve sessions, 3 per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine injection + physical therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical therapy</intervention_name>
    <description>Twelve sessions (3 per week)</description>
    <arm_group_label>Physical Therapy</arm_group_label>
    <other_name>standardized therapeutic exercise program</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine injection</intervention_name>
    <description>blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
    <arm_group_label>Lidocaine injection</arm_group_label>
    <other_name>blocking the Myofascial trigger point</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lidocaine injection + physical therapy</intervention_name>
    <description>blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)</description>
    <arm_group_label>Lidocaine injection + physical therapy</arm_group_label>
    <other_name>blocking plus a standarized therapeutic exercise program</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cervical Pain at least six weeks

          -  At least 40 mm in the VAS

          -  They cannot been received treatment like physical therapy or analgesics

          -  Maximum score of PHQ 16 points

        Exclusion Criteria:

          -  Depression

          -  Fibromyalgia

          -  Cervical Radiculopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luz H Lugo Agudelo, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Antioquia Grupo Rehabilitacion en Salud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica de Las Américas</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ips Universitaria</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2010</study_first_submitted>
  <study_first_submitted_qc>November 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <results_first_submitted>September 27, 2014</results_first_submitted>
  <results_first_submitted_qc>October 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2014</results_first_posted>
  <last_update_submitted>October 4, 2014</last_update_submitted>
  <last_update_submitted_qc>October 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grupo Rehabilitacion en Salud</investigator_affiliation>
    <investigator_full_name>Luz Helena Lugo Agudelo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Myofascial pain</keyword>
  <keyword>Trigger points.</keyword>
  <keyword>Lidocaine injection.</keyword>
  <keyword>Physical therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
    <mesh_term>Musculoskeletal Pain</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In the databases of two general and specialized medical institutions, 762 patients were identified to have non-specific myalgia or muscle disorders diagnoses. A nurse by phone and two medical physiatrists at the hospitals, with over 10 years of research experience evaluated the MPS patients and their medical history.</recruitment_details>
      <pre_assignment_details>The randomization process was performed using permuted blocks.This process was performed by an investigator (HIG) who had no contact with the patients. The allocations to each treatment were placed in consecutive sealed, opaque envelopes, were kept in the research headquarters and were taken to the site according to the number of patients referred.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Physical Therapy</title>
          <description>Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)</description>
        </group>
        <group group_id="P2">
          <title>Lidocaine Injection + Physical Therapy</title>
          <description>Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)</description>
        </group>
        <group group_id="P3">
          <title>Lidocaine Injection</title>
          <description>Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This was calculated with the software &quot;Sample Size Javeriana University&quot; it was took in to account a error type I of 0.05, type II of 0.2, number of measurements before randomization = 1, after performing the randomization = 2, correlation between measurements of 0.6, clinically important difference of 0.35, for a number of patients = 45 each</population>
      <group_list>
        <group group_id="B1">
          <title>Blocking the MTP Plus Physical Therapy</title>
          <description>Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)</description>
        </group>
        <group group_id="B2">
          <title>Physical Therapy</title>
          <description>Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)</description>
        </group>
        <group group_id="B3">
          <title>Blocking the MTP</title>
          <description>Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="11.1"/>
                    <measurement group_id="B2" value="42.6" spread="9.7"/>
                    <measurement group_id="B3" value="37.7" spread="11.8"/>
                    <measurement group_id="B4" value="39.19" spread="11.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant factors</title>
          <description>A patient could have more than one Concomitant factor</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stress</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleeplessness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Longer positions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Muscles with trigger point</title>
          <description>A patient could have more than one trigger point</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Trapezius muscle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Levator scapulae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infraspinatus muscle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physical examination</title>
          <description>A patient could have more than one alteration on the physical examination.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sensitive Alteration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Referred pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local twitch response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Analogue Scale for Pain</title>
          <description>VAS with a score of 0-100, where 100 is the value representing the highest degree of pain and 0 the lowest. Successful treatment was defined as a reduction in pain of at least 20% of the previous score on the VAS after 4 weeks of the initial evaluation, or 14 mm on the VAS; this scale is a reliable pain assessment measure that has been validated previously</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="13.9"/>
                    <measurement group_id="B2" value="68.7" spread="17"/>
                    <measurement group_id="B3" value="64.2" spread="16.2"/>
                    <measurement group_id="B4" value="65.54" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Health Questionnaire – 9</title>
          <description>The PHQ-9 was developed from the Primary Care Evaluation of Mental Disorders. The self-report instrument asks individuals how much they had been bothered by any of the nine problems over the prior two weeks. Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents the severity of depressive symptoms. 0 – 4 None-minimal None, 5 – 9 Mild, 10 – 14 Moderate, 15 – 19 Moderately Severe, 20 – 27 Severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="3.2"/>
                    <measurement group_id="B2" value="5.9" spread="4.2"/>
                    <measurement group_id="B3" value="5.6" spread="3.5"/>
                    <measurement group_id="B4" value="5.72" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Health Questionnaire – 9 How often</title>
          <description>Here we are reporting how often the patient presents symptoms? The PHQ-9 was developed from the Primary Care Evaluation of Mental Disorders. The self-report instrument asks individuals how much they had been bothered by any of the nine problems over the prior two weeks. Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents the severity of depressive symptoms. 0 - 4 None-minimal None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe, 20 - 27 Severe.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Several days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than half the days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nearly every day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of Life SF-36</title>
          <description>The SF-36 consists of 36 items addressing the patient’s perception of their quality of life (QoL) in the following eight domains: physical function (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH), and one item change in health. Sub-scale scores range from 0 to 100, with 100 as the best, most positive QoL in that area and 0 is the worst. There is a total scale score, all subscales range from 0 to 100</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Body pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="14.4"/>
                    <measurement group_id="B2" value="35.2" spread="14.3"/>
                    <measurement group_id="B3" value="38.5" spread="16.4"/>
                    <measurement group_id="B4" value="37.52" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.4" spread="35.0"/>
                    <measurement group_id="B2" value="75.8" spread="38.7"/>
                    <measurement group_id="B3" value="67.2" spread="36.8"/>
                    <measurement group_id="B4" value="69.92" spread="36.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="40"/>
                    <measurement group_id="B2" value="51.1" spread="37.7"/>
                    <measurement group_id="B3" value="42.4" spread="37.6"/>
                    <measurement group_id="B4" value="48.21" spread="48.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.5" spread="17.8"/>
                    <measurement group_id="B2" value="72.5" spread="20.5"/>
                    <measurement group_id="B3" value="81.7" spread="11.9"/>
                    <measurement group_id="B4" value="77.91" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.5" spread="22"/>
                    <measurement group_id="B2" value="68" spread="26.6"/>
                    <measurement group_id="B3" value="71.8" spread="23.6"/>
                    <measurement group_id="B4" value="69.83" spread="24.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="18.3"/>
                    <measurement group_id="B2" value="57.3" spread="21.9"/>
                    <measurement group_id="B3" value="70.7" spread="15.4"/>
                    <measurement group_id="B4" value="65.12" spread="19.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="14.2"/>
                    <measurement group_id="B2" value="65.5" spread="18.9"/>
                    <measurement group_id="B3" value="67.4" spread="17.5"/>
                    <measurement group_id="B4" value="66.93" spread="16.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="13.9"/>
                    <measurement group_id="B2" value="54.7" spread="19.2"/>
                    <measurement group_id="B3" value="60.7" spread="19.3"/>
                    <measurement group_id="B4" value="56.61" spread="17.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Scale</title>
        <description>VAS with a score of 0-100, where 100 is the value representing the highest degree of pain and 0 the lowest. Successful treatment was defined as a reduction in pain of at least 20% of the previous score on the VAS after 4 weeks of the initial evaluation, or 14 mm on the VAS; this scale is a reliable pain assessment measure that has been validated previously</description>
        <time_frame>4 weeks</time_frame>
        <population>Was calculated with the software &quot;Sample Size from Javeriana University&quot;, was taken into account an error type I of 0.05 and error type II of 0.2, number of measurements before randomization = 1, after performing scrambling = 2, correlation between measurements of 0.6, clinically important difference of 0.35, for a total number of = 45 each</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Injection + Physical Therapy</title>
            <description>Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
          </group>
          <group group_id="O3">
            <title>Physical Therapy</title>
            <description>Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale</title>
          <description>VAS with a score of 0-100, where 100 is the value representing the highest degree of pain and 0 the lowest. Successful treatment was defined as a reduction in pain of at least 20% of the previous score on the VAS after 4 weeks of the initial evaluation, or 14 mm on the VAS; this scale is a reliable pain assessment measure that has been validated previously</description>
          <population>Was calculated with the software &quot;Sample Size from Javeriana University&quot;, was taken into account an error type I of 0.05 and error type II of 0.2, number of measurements before randomization = 1, after performing scrambling = 2, correlation between measurements of 0.6, clinically important difference of 0.35, for a total number of = 45 each</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" spread="25.3"/>
                    <measurement group_id="O2" value="44.2" spread="24.9"/>
                    <measurement group_id="O3" value="37.8" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PHQ 9 Function Measured With the Hand Back and Hand Mouth Maneuvers. Complications and Adverse Reactions Need for Rescue Medication</title>
        <description>The PHQ-9 was developed from the Primary Care Evaluation of Mental Disorders. The self-report instrument asks individuals how much they had been bothered by any of the nine problems over the prior two weeks. Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents the severity of depressive symptoms. 0 - 4 None-minimal None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe, 20 - 27 Severe</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Injection + Physical Therapy</title>
            <description>Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
          </group>
          <group group_id="O3">
            <title>Physical Therapy</title>
            <description>Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)</description>
          </group>
        </group_list>
        <measure>
          <title>PHQ 9 Function Measured With the Hand Back and Hand Mouth Maneuvers. Complications and Adverse Reactions Need for Rescue Medication</title>
          <description>The PHQ-9 was developed from the Primary Care Evaluation of Mental Disorders. The self-report instrument asks individuals how much they had been bothered by any of the nine problems over the prior two weeks. Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents the severity of depressive symptoms. 0 - 4 None-minimal None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe, 20 - 27 Severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="3.647"/>
                    <measurement group_id="O2" value="4.44" spread="3.03"/>
                    <measurement group_id="O3" value="4.43" spread="4.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life SF-36</title>
        <description>The SF-36 consists of 36 items addressing the patient's perception of their quality of life (QoL) in the following eight domains: physical function (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH), and one item change in health. Sub-scale scores range from 0 to 100, with 100 as the best, most positive QoL in that area and 0 is the worst. There is a total scale score, all subscales range from 0 to 100. This scale was validated in Colombia.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Injection + Physical Therapy</title>
            <description>Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
          </group>
          <group group_id="O3">
            <title>Physical Therapy</title>
            <description>Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life SF-36</title>
          <description>The SF-36 consists of 36 items addressing the patient's perception of their quality of life (QoL) in the following eight domains: physical function (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH), and one item change in health. Sub-scale scores range from 0 to 100, with 100 as the best, most positive QoL in that area and 0 is the worst. There is a total scale score, all subscales range from 0 to 100. This scale was validated in Colombia.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changing Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" spread="18.1"/>
                    <measurement group_id="O2" value="67.8" spread="16.05"/>
                    <measurement group_id="O3" value="60.93" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" spread="18.4"/>
                    <measurement group_id="O2" value="51.78" spread="15.70"/>
                    <measurement group_id="O3" value="57.12" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional performance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" spread="35.1"/>
                    <measurement group_id="O2" value="78.76" spread="33.24"/>
                    <measurement group_id="O3" value="85.85" spread="27.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical performance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" spread="40.5"/>
                    <measurement group_id="O2" value="74.39" spread="33.3"/>
                    <measurement group_id="O3" value="73.84" spread="34.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" spread="13.2"/>
                    <measurement group_id="O2" value="86.83" spread="11.55"/>
                    <measurement group_id="O3" value="82.79" spread="15.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="20.7"/>
                    <measurement group_id="O2" value="78.15" spread="20.44"/>
                    <measurement group_id="O3" value="81.51" spread="22.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="16.7"/>
                    <measurement group_id="O2" value="73.54" spread="13.43"/>
                    <measurement group_id="O3" value="65.70" spread="20.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="16.6"/>
                    <measurement group_id="O2" value="69.95" spread="17.57"/>
                    <measurement group_id="O3" value="70.05" spread="19.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" spread="16"/>
                    <measurement group_id="O2" value="62.56" spread="17.32"/>
                    <measurement group_id="O3" value="59.88" spread="19.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Scale</title>
        <description>VAS with a score of 0-100, where 100 is the value representing the highest degree of pain and 0 the lowest. Successful treatment was defined as a reduction in pain of at least 20% of the previous score on the VAS after 4 weeks of the initial evaluation, or 14 mm on the VAS; this scale is a reliable pain assessment measure that has been validated previously</description>
        <time_frame>12 weeks</time_frame>
        <population>Was calculated with the software &quot;Sample Size from Javeriana University&quot;, was taken into account an error type I of 0.05 and error type II of 0.2, number of measurements before randomization = 1, after performing scrambling = 2, correlation between measurements of 0.6, clinically important difference of 0.35, for a total number of = 45 each</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Injection + Physical Therapy</title>
            <description>Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
          </group>
          <group group_id="O3">
            <title>Physical Therapy</title>
            <description>Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale</title>
          <description>VAS with a score of 0-100, where 100 is the value representing the highest degree of pain and 0 the lowest. Successful treatment was defined as a reduction in pain of at least 20% of the previous score on the VAS after 4 weeks of the initial evaluation, or 14 mm on the VAS; this scale is a reliable pain assessment measure that has been validated previously</description>
          <population>Was calculated with the software &quot;Sample Size from Javeriana University&quot;, was taken into account an error type I of 0.05 and error type II of 0.2, number of measurements before randomization = 1, after performing scrambling = 2, correlation between measurements of 0.6, clinically important difference of 0.35, for a total number of = 45 each</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="21.8"/>
                    <measurement group_id="O2" value="28.8" spread="22.3"/>
                    <measurement group_id="O3" value="28.2" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PHQ 9 Function Measured With the Hand Back and Hand Mouth Maneuvers. Complications and Adverse Reactions Need for Rescue Medication</title>
        <description>The PHQ-9 was developed from the Primary Care Evaluation of Mental Disorders. The self-report instrument asks individuals how much they had been bothered by any of the nine problems over the prior two weeks. Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents the severity of depressive symptoms. 0 - 4 None-minimal None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe, 20 - 27 Severe</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Injection + Physical Therapy</title>
            <description>Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
          </group>
          <group group_id="O3">
            <title>Physical Therapy</title>
            <description>Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)</description>
          </group>
        </group_list>
        <measure>
          <title>PHQ 9 Function Measured With the Hand Back and Hand Mouth Maneuvers. Complications and Adverse Reactions Need for Rescue Medication</title>
          <description>The PHQ-9 was developed from the Primary Care Evaluation of Mental Disorders. The self-report instrument asks individuals how much they had been bothered by any of the nine problems over the prior two weeks. Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents the severity of depressive symptoms. 0 - 4 None-minimal None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe, 20 - 27 Severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" spread="3.97"/>
                    <measurement group_id="O2" value="3.16" spread="2.81"/>
                    <measurement group_id="O3" value="4.12" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life SF-36</title>
        <description>The SF-36 consists of 36 items addressing the patient's perception of their quality of life (QoL) in the following eight domains: physical function (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH), and one item change in health. Sub-scale scores range from 0 to 100, with 100 as the best, most positive QoL in that area and 0 is the worst. There is a total scale score, all subscales range from 0 to 100. This scale was validated in Colombia.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Injection + Physical Therapy</title>
            <description>Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
          </group>
          <group group_id="O3">
            <title>Physical Therapy</title>
            <description>Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life SF-36</title>
          <description>The SF-36 consists of 36 items addressing the patient's perception of their quality of life (QoL) in the following eight domains: physical function (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH), and one item change in health. Sub-scale scores range from 0 to 100, with 100 as the best, most positive QoL in that area and 0 is the worst. There is a total scale score, all subscales range from 0 to 100. This scale was validated in Colombia.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changing Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="18.67"/>
                    <measurement group_id="O2" value="70.23" spread="17.11"/>
                    <measurement group_id="O3" value="69.76" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.58" spread="20.09"/>
                    <measurement group_id="O2" value="61.19" spread="17.67"/>
                    <measurement group_id="O3" value="65.66" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional performance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.25" spread="32.11"/>
                    <measurement group_id="O2" value="90.60" spread="21.15"/>
                    <measurement group_id="O3" value="84.13" spread="32.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical performance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.88" spread="30.48"/>
                    <measurement group_id="O2" value="87.79" spread="22.07"/>
                    <measurement group_id="O3" value="82.5" spread="31.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.75" spread="16.94"/>
                    <measurement group_id="O2" value="90" spread="9.06"/>
                    <measurement group_id="O3" value="89.13" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" spread="20.99"/>
                    <measurement group_id="O2" value="83.28" spread="17.44"/>
                    <measurement group_id="O3" value="83.05" spread="20.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.67" spread="17.26"/>
                    <measurement group_id="O2" value="77.44" spread="12.50"/>
                    <measurement group_id="O3" value="68.25" spread="22.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="16.79"/>
                    <measurement group_id="O2" value="78.95" spread="14.03"/>
                    <measurement group_id="O3" value="71.32" spread="17.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.38" spread="16.11"/>
                    <measurement group_id="O2" value="69.64" spread="16.17"/>
                    <measurement group_id="O3" value="61.95" spread="18.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine Injection + Physical Therapy</title>
          <description>Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)</description>
        </group>
        <group group_id="E2">
          <title>Physical Therapy</title>
          <description>Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)</description>
        </group>
        <group group_id="E3">
          <title>Lidocaine Injection</title>
          <description>Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Blood and lymphatic</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hematomas</sub_title>
                <description>shallow hematoma after injection of lidocaine without infectious or hemorrhagic complications.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Minimal bleeding after injection of lidocaine.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The therapists were not the same throughout the investigation, however all were standardized to interventions; especilaistas doctors who applied the injections were different. No specific measure of patient-centered operation is used.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Luz Helena Lugo, Head of Research Group Rehabilitation in Health</name_or_title>
      <organization>university of Antioquia, Research Group Rehabilitation in Health</organization>
      <phone>+57 4 2196475</phone>
      <email>luzh.lugo@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

